新型U500门冬胰岛素制剂的药代动力学与药效学:在1型糖尿病患者中开展的一项随机双盲交叉研究
这项单中心、随机、双盲交叉研究在38例体重≤100 kg且每日胰岛素总量<1.2单位/kg的1型糖尿病男性患者中,比较单次皮下注射0.3单位/kg的AT278 U500与IAsp U100后8小时正血糖钳夹的结果。AT278 U500的血清出现时间提前6分钟,起效时间提前10分钟,早期胰岛素暴露和降糖效应显著更高,总体暴露和降糖效应相当,未观察到显著安全性问题。
要点
- AT278 U500的血清出现时间较IAsp U100提前6分钟(P<0.0001)。
- AT278 U500的起效时间较IAsp U100提前10分钟(P<0.0001)。
- AT278 U500前30分钟降糖效应为IAsp U100的8.9倍(95%CI 5.96, 17.46)。
核心结论
- AT278 U500在研究人群中较IAsp U100吸收更快、起效更快,具有速效特征且注射剂量体积更小。
研究设计与样本
- 单中心、随机、双盲、交叉研究,纳入38例男性1型糖尿病患者(体重≤100 kg,每日胰岛素总量<1.2单位/kg)。
- 受试者单次皮下注射AT278 U500或IAsp U100 0.3单位/kg,随后在无基础胰岛素条件下进行8小时正血糖钳夹。
主要发现
- AT278 U500的血清出现时间较IAsp U100提前6分钟(P<0.0001),达到最大浓度50%的时间快23分钟(P<0.0001)。
- AT278 U500前30分钟胰岛素暴露为IAsp U100的4.0倍(95%CI 3.29, 4.90),前60分钟为1.5倍(95%CI 1.35, 1.76),给药后90分钟内统计学优于IAsp U100(P<0.05)。
- AT278 U500起效时间较IAsp U100提前10分钟(P<0.0001),达到最大葡萄糖输注率50%的时间快20分钟(P<0.0001)。
- AT278 U500前30分钟降糖效应为IAsp U100的8.9倍(95%CI 5.96, 17.46),前60分钟为2.4倍(95%CI 1.92, 3.22),给药后2小时内统计学优于IAsp U100(P<0.0001)。
- 总体胰岛素暴露和总体降糖效应与IAsp U100相当,未观察到显著安全性问题。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the pharmacokinetics, pharmacodynamics, and safety of a novel U500 insulin aspart formulation (AT278 U500) compared with insulin aspart (IAsp U100). RESEARCH DESIGN AND METHODS: This single-center, randomized, double-blind study was conducted in 38 men with type 1 diabetes (body weight ≤100 kg and total insulin dose <1.2 units/kg/day). Participants received a single dose of either AT278 U500 or IAsp U100 (0.3 units/kg s.c.) in a crossover design, followed by an 8-h euglycemic clamp in the absence of basal insulin. RESULTS: With AT278 U500, onset of appearance in serum was 6 min earlier (P < 0.0001) and reached 50% of maximum concentration 23 min faster (P < 0.0001). Insulin exposure with AT278 U500 was 4.0-fold higher within the first 30 min (95% CI 3.29, 4.90), 1.5-fold higher within the first 60 min (95% CI 1.35, 1.76), and statistically superior up to 90 min postdose (P < 0.05). With AT278 U500, onset of action was 10 min earlier (P < 0.0001) and reached 50% of maximum glucose infusion rate 20 min faster (P < 0.0001). The glucose-lowering effect with AT278 U500 was 8.9-fold higher within the first 30 min (95% CI 5.96, 17.46), 2.4-fold higher within the first 60 min (95% CI 1.92, 3.22), and statistically superior up to 2 h postdose (P < 0.0001). Overall insulin exposure and glucose-lowering effect were comparable. No significant safety findings were observed. CONCLUSIONS: AT278 U500 offers rapid-acting characteristics in a reduced dose volume, with accelerated absorption and onset of action compared with IAsp U100 in the studied population.
引用
- Svehlikova E, Ashcroft NL, Gatschelhofer C, et al. Pharmacokinetics and Pharmacodynamics of a Novel U500 Insulin Aspart Formulation: A Randomized, Double-Blind, Crossover Study in People With Type 1 Diabetes. Diabetes Care. 2023. PMID: 36710473. doi:10.2337/dc22-1054
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。